EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Wed, 26.02.2025
Gerresheimer delivers solid results in the financial year 2024 despite market headwinds
Organic growth: revenue +2.9%, adjusted EBITDA +4.1%
Destocking in vial business partially offset by strong growth in medical devices
Growth strategy execution: capacity expansions and higher revenue share from solutions for biologics
Bormioli Pharma to boos...
Gerresheimer AG confirms discussions with private equity investors on potential takeover offer
Düsseldorf, February 7, 2025 – The Executive Board of Gerresheimer AG (ISIN: DE000A0LD6E6, "Gerresheimer") reacts to press reports and confirms that Gerresheimer is in early-stage discussions with private equity investors who have expressed, on an infor...
Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*
Innovative combination product of furosemide and on-body device
Ready-to-market device designed, developed and manufactured by Gerresheimer
Patented device technology for precise administration
Düsseldorf, Germany, December 16, 2024. Gerresheimer, an innovative system a...
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
Complementary product portfolio and broad footprint of production sites in Europe
Strengthening the market position as a full-service provider for the pharma and biotech industry
Strategic reset of Moulded Glass business
Düsseldo...
Gerresheimer builds new production capacities for glass syringes at Skopje site
Expansion of the site in the Republic of North Macedonia with a new production hall for glass syringes
Total investment volume of over EUR 100 million
Around 250 new jobs for skilled workers from the region
Ramp-up of syringe production starting by the end of 2024
...
Solar power for Gerresheimer site in Momignies, Belgium
2.3 MWp rooftop photovoltaic system on production building
Gerresheimer increases share of green electricity in its energy supply
Goal for 2030: 100% electricity from renewable sources
Duesseldorf/Momignies, October 14, 2024. Gerresheimer, an innovative system and solution partner and a glo...
Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025
Düsseldorf, September 30, 2024 – Gerresheimer AG (ISIN: DE000A0LD6E6) is adjusting its growth guidance for 2024 and 2025 due to the significantly slower than expected market recovery 2024 and lower anticipated market growth in 2025 in the vial market. The guidance is also affected ...
Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”
Market advances adoption of ready-to-use containers
Improved operational efficiency in pharmaceutical manufacturing processes
Increased patient safety with high-quality sterile primary packaging
Düsseldorf, September 26, 2024. Gerresheimer AG (MDAX: G...
Gerresheimer: EcoVadis Gold with further improved score
Gerresheimer among the top 3 % of all rated companies
Overall result increased to 76/100 points
Award underlines consistent implementation of the sustainability strategy
Düsseldorf, September 16, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the ph...
Gerresheimer: EcoVadis Gold with further improved score
Gerresheimer among the top 3 % of all rated companies
Overall result increased to 76/100 points
Award underlines consistent implementation of the sustainability strategy
Düsseldorf, September 16, 2024 - Gerresheimer, an innovative systems and solutions provider and global partner for the ph...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .